Neuracle raises RMB 60M for clinical brain-computer interface products
Summary
Neuracle Technology has completed a new financing round raising RMB 60 million ($8.3 million), bringing its total funding to over RMB 100 million. The round was led by China Control Fund, China Development Fund, China Development Frontier Fund, and BV Baidu Ventures. The Jiangsu-based company develops end-to-end BCI solutions for neurological diagnosis, treatment, and rehabilitation.
Why it matters
Neuracle's platform powers products across brain research and neurological diagnostics, with over 30% market share in China's BCI research market in 2018. The company's EEG and evoked potential systems are core components of China's medical device innovation strategy. The funding will accelerate R&D of clinical products including minimally invasive implant feedback therapy and BCI-based intelligent rehabilitation for stroke recovery.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial